BIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Republic of Korea.
Department of Internal Medicine, College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea.
Int J Mol Sci. 2023 Mar 30;24(7):6495. doi: 10.3390/ijms24076495.
This systematic review aimed to assess the prognostic significance of programmed cell death-ligand 1 (PDL-1) and programmed cell death protein 1 (PD-1) in hepatocellular carcinoma (HCC). Medline, EMBASE, and Cochrane Library database searches were conducted, revealing nine relevant cohort studies (seven PDL-1 and three PD-1). Our meta-analysis showed that PD-1/PDL-1 was a marker of poor survival, regardless of the assessment method (PD-1 overall survival (OS): hazard ratio (HR) 2.40; 95% confidence interval (CI), 1.30-4.42; disease-free survival (DFS): HR 2.12; 95% CI, 1.45-3.10; PDL-1: OS: HR 3.61; 95% CI, 2.75-4.75; and DFS: HR 2.74; 95% CI, 2.09-3.59). Additionally, high level of PD-1/PDL-1 expression was associated with aging, multiple tumors, high alpha-fetoprotein levels, and advanced Barcelona Clinic Liver Cancer stage. This high level significantly predicted a poor prognosis for HCC, suggesting that anti-PD-1 therapy is plausible for patients with HCC. Furthermore, HIF-1 induces PD-1 expression, and PD1SOCS3 is associated with a better prognosis. Taken together, combination therapy may be the key to effective immunotherapy. Thus, exploring other markers, such as HIF-1 and SOCS3, along with PD-1/PDL-1 immunotherapy, may lead to improved outcomes.
本系统评价旨在评估程序性细胞死亡配体 1（PDL-1）和程序性细胞死亡蛋白 1（PD-1）在肝细胞癌（HCC）中的预后意义。通过对 Medline、EMBASE 和 Cochrane Library 数据库进行检索，共发现 9 项相关的队列研究（7 项 PD-1，3 项 PD-1）。我们的荟萃分析表明，PD-1/PDL-1 是生存不良的标志物，无论评估方法如何（PD-1 总生存（OS）：风险比（HR）2.40；95%置信区间（CI），1.30-4.42；无病生存（DFS）：HR 2.12；95%CI，1.45-3.10；PDL-1：OS：HR 3.61；95%CI，2.75-4.75；DFS：HR 2.74；95%CI，2.09-3.59）。此外，高水平的 PD-1/PDL-1 表达与年龄较大、多个肿瘤、高甲胎蛋白水平和巴塞罗那临床肝癌分期较高有关。高水平的 PD-1/PDL-1 表达显著预示 HCC 的预后不良，表明抗 PD-1 治疗可能适用于 HCC 患者。此外，HIF-1 诱导 PD-1 表达，PD1SOCS3 与更好的预后相关。总之，联合治疗可能是有效免疫治疗的关键。因此，探索其他标志物，如 HIF-1 和 SOCS3，以及 PD-1/PDL-1 免疫治疗，可能会改善治疗效果。
Zotero 插件
